Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9269 Tagraxofusp-erzs Elzonris 10mcg Immunotherapy Recombinant Fusion Protein IL3/CD123 No 2018 Oct 1, 2019 In Use
NA Talazoparib Talzenna 0.25mg, 1mg Chemotherapy Enzyme Inhibitor PARP Yes 2018 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct 1, 2019 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
J9036 Bendamustine HCL Belrapzo 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2018 Jul 1, 2019 In Use
NA Gilteritinib Xospata 40mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2018 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
Q5113 Trastuzumab-pkrb Herzuma 10mg Immunotherapy Monoclonal Antibody HER2 No 2018 Jul 1, 2019 In Use
J9198 Gemcitabine HCl Infugem 100mg Chemotherapy Antimetabolite Pyrimidine Analog No 2018 Jul 1, 2020 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Binimetinib Mektovi 15mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2018 In Use
NA Abemaciclib Verzenio 150 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Rucaparib Rubraca 300 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
J8612 Methotrexate (xatmep) Xatmep 2.5mg Chemotherapy Antimetabolite Folic Acid Analog Yes 2017 Jun 10, 2024 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Ribociclib Kisqali 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.